Cases (n=370) Controls (n=10,357)
Mean Age ± SD (y) 67.6 ± 12.2 59.7 ± 13.5
Mean diabetes duration 10.5 ± 6.7 7.2 ± 6.4
Males (n) 241 (65.1%) 5,643 (54.5%)
Females (n) 129 (34.9%) 4714 (45.5%)
Nephropathy (n) 28 (7.6 %) 541 (5.2%)
Neuropathy (n) 19 (5.1%) 396 (3.8%)
Retinopathy (n) 11 (3.0%) 215 (2.1%)
Peripheral artery disease 44 (11.9%) 501 (4.8%)
Alcohol 14 (3.8%) 366 (3.5%)
Previous AMI (n) 80 (21.6%) 77 (0.7%)
Atrial fibrillation 49 (13.2%) 848 (8.2%)
Insulin users(n) 198 (53.5%) 4,547 (43.9%)
Biguanid users (n) 195 (52.6%) 7,646 (73.8%)
β-cell stimulating users (n) 137 (37.0%) 3,913 (37.8%)
Glitazones users (n) 2 (0.5%) 142 (1.4%)
DPP-4 inhibitors users (n) 22 (5.9%) 1,159 (11.2%)
GLP-1: Liraglutide users (n) 14 (3.8%) 1,586 (15.3%)
GLP-1: Exenatide users (n) 10 (2.7%) 396 (3.8%)
Antiarrhythmic drugs 44 (11.9%) 794 (7.7%)
Hypertension (n) 328 (88.6%) 8,616 (83.2%)
Statins users (n) 279 (75.4%) 8,096 (78.2%)
Table 2: Baseline characteristics of DM cases and controls (n=10,727) used in the covariate adjusted analyses.